Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 10;13(6):e15563.
doi: 10.7759/cureus.15563. eCollection 2021 Jun.

Past, Present, and Future of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer

Mona Mishra  1 , Nilanchali Singh  2 , Prafull Ghatage  3
Affiliations
Review

Past, Present, and Future of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer

Mona Mishra et al. Cureus. .

Abstract

Hyperthermic intraperitoneal chemotherapy (HIPEC), along with optimal cytoreductive surgery, has been debated to be a viable option for the treatment of advanced epithelial ovarian cancer with peritoneal carcinomatosis. HIPEC is associated with a direct and improved penetration of chemotherapy drugs into the affected tissue and is associated with fewer systemic side effects. There is no standard protocol for the use of HIPEC in advanced ovarian cancer. Hence, there is controversy over the timing, dose, duration, and efficacy of HIPEC. In this review, the history, technique, current evidence, recommendations, and future directions of HIPEC are discussed.

Keywords: clinical trials; hipec; hyperthermic intraperitoneal chemotherapy; ovarian cancer; technique.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Diagrammatic representation of HIPEC
HIPEC: hyperthermic intraperitoneal chemotherapy
See this image and copyright information in PMC

References

    1. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a Gynecologic Oncology Group study. Tewari D, Java JJ, Salani R, et al. J Clin Oncol. 2015;33:1460–1466. - PMC - PubMed
    1. Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo. Kusumoto T, Holden SA, Ara G, Teicher BA. Int J Hyperthermia. 1995;11:575–586. - PubMed
    1. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. van de Vaart PJ, van der Vange N, Zoetmulder FA, et al. Eur J Cancer. 1998;34:148–154. - PubMed
    1. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Panteix G, Beaujard A, Garbit F, et al. https://pubmed.ncbi.nlm.nih.gov/12168946/ Anticancer Res. 2002;22:1329–1336. - PubMed
    1. Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells. Ohno S, Siddik ZH, Kido Y, et al. Cancer Chemother Pharmacol. 1994;34:302–306. - PubMed

LinkOut - more resources